To evaluate the adenoviral therapeutic efficiency of targeting either CAR or CD46 in bladder cancer cells, several human bladder cancer cells, including EJ, 5637, J82, T24, and HT-1376, were evaluated for their transduction susceptibility to Ad5 and Ad5/35. This evidence concerns the gene CD46 and urinary bladder carcinoma.